Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2024 12:07 ET | Source: Block & Leviton LLP

SHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & Leviton

Aerovate Therapeutics (Nasdaq: AVTE) investigated for securities law violations by Block & Leviton.
November 22, 2023 07:00 ET | Source: Algernon Pharmaceuticals

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
August 04, 2022 09:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
August 03, 2022 16:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499

HANOVER, MD, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
April 29, 2022 18:32 ET | Source: 180 Life Sciences Corp.

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 monthsThe treatment arm...
August 06, 2021 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST

HANOVER, Md., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...
July 19, 2021 01:00 ET | Source: Bone Therapeutics SA

Bone Therapeutics fait le point sur l’avancement de ses études cliniques

INFORMATION RÉGLEMENTÉE Les premiers résultats de la phase III évaluant JTA-004 sont prévus pour la première moitié de septembre La phase IIb évaluant ALLOB est en cours malgré un...
July 19, 2021 01:00 ET | Source: Bone Therapeutics SA

Bone Therapeutics provides update on the progress of clinical studies

REGULATED INFORMATION JTA-004 Phase III top-line results planned first half September ALLOB Phase IIb currently on track but recruitment slow due to COVID-19 pandemic Gosselies,...
July 13, 2021 08:00 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTrial expanded to South America, with regulatory approvals for Argentina and BrazilTarget trial enrollment...
January 12, 2021 01:00 ET | Source: Bone Therapeutics SA

Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

REGULATED INFORMATION All patients expected to be recruited in H1 2022 Topline results anticipated in H2 2022 Gosselies, Belgium, 12 January 2020, 7am CEST – BONE...

Next Page keyboard_arrow_right